Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Dyno Therapeutics, a US-based gene therapy platform developer spun out of Harvard Medical School, emerged from stealth yesterday with $9m in seed financing co-led by Polaris Partners and CRV to commercialise treatments for several disease populations. Dyno Therapeutics has built an artificial intelligence-driven drug design platform for identifying viral vectors for gene therapies to gain access to the body, targeting ophthalmic, muscle, central nervous system and liver diseases. Founded in 2018, Dyno hopes to sustain operations with fees from its collaboration agreements and does not anticipate raising further equity funding. Alan Crane, entrepreneur partner at Polaris and a co-founder at Dyno, and Dylan Morris, general partner at CRV, have both joined the board of directors, with Crane appointed executive chairman.
Entropica Labs, a Singapore-based quantum computing software architecture developer based on National University of Singapore (NUS) technology, has secured $1.8m of seed funding led by deep tech-focused venture firm…
